{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:16:08Z","timestamp":1794539768400,"version":"4.9.1"},"reference-count":26,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"accepted":{"date-parts":[[2026,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare camrelizumab plus capecitabine and oxaliplatin followed by camrelizumab plus apatinib (camre+CAPOX followed by camre+apa), CAPOX alone, and camrelizumab plus CAPOX followed by camrelizumab (camre+CAPOX followed by camre) as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Randomised, open label, phase 3 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>75 hospitals in China, 13 March 2019 to 16 August 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>885 adults (\u226518 years) with previously untreated, human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients were randomised (2:2:1) to receive camre+CAPOX followed by camre+apa, CAPOX only, or camre+CAPOX followed by camre, stratified by Eastern Cooperative Oncology Group performance status, peritoneal metastasis, and programmed death ligand 1 (PD-L1) combined positive score. Assignment to camre+CAPOX followed by camre was introduced midway through enrolment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The primary endpoint was overall survival for camre+CAPOX followed by camre+apa versus CAPOX alone in the PD-L1 positive population (combined positive score &gt;1) and the overall population who received at least one dose of study drug. Comparisons of camre+CAPOX followed by camre versus CAPOX alone and of camre+CAPOX followed by camre+apa versus camre+CAPOX\u2013camre were descriptive. Safety was assessed in all patients who received at least one dose of study drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      352 patients received camre+CAPOX followed by camre+apa, 349 received CAPOX alone, and 177 received camre+CAPOX followed by camre. At the time of data cut off, 454 of 592 (76.7%) deaths had occurred in the PD-L1 positive population and 709 of 878 (80.8%) in the overall population. Overall survival was longer with camre+CAPOX followed by camre+apa than with CAPOX alone in the PD-L1 positive population (median 15.0\n                      <jats:italic>v<\/jats:italic>\n                      12.5 months; hazard ratio 0.80 (95% CI 0.65 to 0.98); one sided P=0.02) and in the overall population (median 13.5\n                      <jats:italic>v<\/jats:italic>\n                      12.1 months; hazard ratio 0.80 (0.68 to 0.94); one sided P=0.004). Use of camre+CAPOX followed by camre also showed longer overall survival versus CAPOX in the PD-L1 positive population (median 15.3\n                      <jats:italic>v<\/jats:italic>\n                      12.5 months; hazard ratio 0.76 (0.58 to 0.97); one sided nominal P=0.01) and overall population (median 14.2\n                      <jats:italic>v<\/jats:italic>\n                      12.1 months; hazard ratio 0.80 (0.65 to 0.98); one sided nominal P=0.02). No overall survival benefit was observed with camre+CAPOX followed by camre+apa versus camre+CAPOX followed by camre. Treatment related adverse events of grade \u22653 occurred in 239 of 352 (67.9%) patients in the camre+CAPOX followed by camre+apa group, 158 of 349 (45.3%) in the CAPOX alone group, and 83 of 177 (46.9%) in the camre+CAPOX followed by camre group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Initial treatment with camrelizumab plus CAPOX followed by camrelizumab based maintenance was associated with longer overall survival than CAPOX alone in human epidermal growth factor receptor 2 (HER2) negative, unresectable, locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Exploratory comparisons between the two camrelizumab based regimens showed no additional survival benefit, with higher rates of treatment related adverse events of grade \u22653 and treatment discontinuations when apatinib was added during maintenance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT03813784\" ext-link-type=\"clintrialgov\">NCT03813784<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmj-2025-086115","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:10:14Z","timestamp":1773317414000},"page":"e086115","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial"],"prefix":"10.1136","volume":"392","clinical-trial-number":[{"clinical-trial-number":"nct03813784","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4063-9813","authenticated-orcid":false,"given":"Zhi","family":"Peng","sequence":"first","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China"},{"name":"Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumour, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Digestive Tumour, Gansu Provincial Cancer Hospital, Lanzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shanxi Provincial Cancer Hospital, Taiyuan, China"},{"name":"Shanxi Hospital, Cancer Hospital, Chinese Academy of Medical Sciences, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[{"name":"Division of Life Sciences and Medicine, First Affiliated Hospital of USTC, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Chengde Medical College, Chengde, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanxi Provincial Hospital of Traditional Chinese Medicine, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangsheng","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxiang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Affiliated Hospital of Xi\u2019an Jiaotong University, Xi\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Surgery (Third Division), Fourth Hospital of Hebei Medical University, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Lin","sequence":"additional","affiliation":[{"name":"Cancer Centre, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"},{"name":"Guangdong Gastrointestinal Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirong","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Bai","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiru","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-4756","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China"},{"name":"Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumour, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026031209100652000_392.mar12_2.e086115.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026031209100652000_392.mar12_2.e086115.2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0578"},{"key":"2026031209100652000_392.mar12_2.e086115.3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30328-0"},{"key":"2026031209100652000_392.mar12_2.e086115.4","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6627-y"},{"key":"2026031209100652000_392.mar12_2.e086115.5","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000423"},{"key":"2026031209100652000_392.mar12_2.e086115.6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi064"},{"key":"2026031209100652000_392.mar12_2.e086115.7","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2010.076570"},{"key":"2026031209100652000_392.mar12_2.e086115.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"2026031209100652000_392.mar12_2.e086115.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"2026031209100652000_392.mar12_2.e086115.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6"},{"key":"2026031209100652000_392.mar12_2.e086115.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918"},{"key":"2026031209100652000_392.mar12_2.e086115.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876"},{"key":"2026031209100652000_392.mar12_2.e086115.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"2026031209100652000_392.mar12_2.e086115.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995"},{"key":"2026031209100652000_392.mar12_2.e086115.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.8585"},{"key":"2026031209100652000_392.mar12_2.e086115.16","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0903-9"},{"key":"2026031209100652000_392.mar12_2.e086115.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112437"},{"key":"2026031209100652000_392.mar12_2.e086115.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2484"},{"key":"2026031209100652000_392.mar12_2.e086115.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4691"},{"key":"2026031209100652000_392.mar12_2.e086115.20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370"},{"key":"2026031209100652000_392.mar12_2.e086115.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00961-3"},{"key":"2026031209100652000_392.mar12_2.e086115.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12836"},{"key":"2026031209100652000_392.mar12_2.e086115.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.018"},{"key":"2026031209100652000_392.mar12_2.e086115.24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30365-9"},{"key":"2026031209100652000_392.mar12_2.e086115.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30110-8"},{"key":"2026031209100652000_392.mar12_2.e086115.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2025-086115","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2025-086115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:10:15Z","timestamp":1773331815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2025-086115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":26,"alternative-id":["10.1136\/bmj-2025-086115"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2025-086115","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}